Skip to main content
2024 CRT Conference Main banner
Back

CRT 2024

Symposium

MDEpiNet at CRT [Non-CME]

Discussion Panel

Saturday, March 9, 2024
4:05 PM – 4:30 PM ET

    Panel Moderator(s)

  • Kenneth J. Cavanaugh, Jr., PhD

    Deputy Director, Office of Cardiovascular Devices
    U.S. Food and Drug Administration
    Silver Spring, Maryland, United States

    No relationships to disclose

  • Changfu Wu, PhD

    SBRBPAS Expert
    Food and Drug Administration
    Silver Spring, Maryland, United States

    Disclosure(s): No financial relationships to disclose

    • Panel Discussant(s)

  • David Erlinge, MD, PhD

    Professor, Consultant Interventional Cardiology
    Lund University
    Lund, Sweden

    No relationships to disclose

  • Andrew Farb, MD

    Chief Medical Officer, Office of Cardiovascular Devices
    U.S. Food and Drug Administration
    Silver Spring, Maryland, United States

    No relationships to disclose

  • C. Michael Gibson, MD

    Professor of Medicine
    Beth Israel Deaconess Medical Center
    Boston, Massachusetts, United States

    Disclosure(s): Absolutys: Shareholder (Ongoing); Angel Medical Systems, Inc.: Consultant (Ongoing); AstraZeneca Pharmaceuticals: Consultant (Ongoing); Bayer HealthCare: Consultant (Ongoing); Beren Therapeutics: Consultant (Ongoing); Bioclinica: Consultant (Ongoing); BOEHRINGER INGELHEIM IT.SpA.: Consultant (Ongoing); Boston Clinical Research Institute: Consultant (Ongoing), Owner/Co-Owner Founder/Co-Founder (Ongoing); Boston Scientific: Consultant (Ongoing); Bristol Meyers Squibb: Consultant (Ongoing); Cardiovascular Research Foundation: Consultant (Ongoing); CeleCor Therapeutics: Consultant (Ongoing); CSL-Behring: Consultant (Ongoing), Grant/Research Support (Ongoing); Duke Clinical Research Institute: Consultant (Ongoing); Dyad Medical: Shareholder (Ongoing); Esperion: Consultant (Ongoing); EXCITE International: Advisor (Ongoing); Fortress Biotech: Consultant (Ongoing), Consultant (Ongoing), Shareholder (Ongoing), Shareholder (Ongoing); Gilead: Consultant (Ongoing); Inari: Consultant (Ongoing); Janssen Research & Development LLC: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Johnson & Johnson: Consultant (Ongoing), Grant/Research Support (Ongoing); MashUP MD: Consultant (Ongoing); MD Magazine: Consultant (Ongoing); Merck Pharmaceuticals: Consultant (Ongoing); MicroPort Medical: Consultant (Ongoing); MJH Life Sciences: Consultant (Ongoing); New Amsterdam Pharma: Consultant (Ongoing); nference: Shareholder (Ongoing); Novartis Pharmaceuticals: Consultant (Ongoing); NovoNordisk: Consultant (Ongoing); PERT Consortium: Consultant (Ongoing); Pfizer: Consultant (Ongoing); PhaseBio: Consultant (Ongoing); plx pharma: Consultant (Ongoing); Revance Therapeutics: Consultant (Ongoing); Samsung: Consultant (Ongoing); SCAD Alliance: Consultant (Ongoing); SCAI: Consultant (Ongoing); SFJ: Consultant (Ongoing); Somahlution/Marizyme: Consultant (Ongoing); UpToDate in Cardiovascular Medicine: Royalties (Ongoing); Vecutra: Consultant (Ongoing); WebMD: Consultant (Ongoing); Woman As One: Consultant (Ongoing)

  • GH

    Graeme Hickey

    Disclosure information not submitted.

  • JS

    Josh Smale

    Disclosure information not submitted.

  • Ron Waksman, MD, MSCAI

    Director, Cardiovascular Research and Advanced Education
    MedStar Washington Hospital Center, MedStar Heart and Vascular Institute
    Washington, District of Columbia, United States

    Disclosure information not submitted.